Raymond James raises Edgewise Therapeutics price target on FDA feedback
Raymond James raised its price target on Edgewise Therapeutics (EWTX) to $85 from $66, maintaining a Strong Buy rating. This follows FDA feedback on EDG-7500 for hypertrophic cardiomyopathy. EWTX stock is up 116% over the past year and 51% year-to-date, trading at $38.90. The company recently sold its muscular dystrophy business for $1.55 billion, focusing on cardiovascular disease. Analysts William Blair and H.C. Wainwright also issued positive ratings and targets.
How this was made
The 30-second read
Why it matters
Analyst upgrades could attract new capital and improve liquidity.
Market read
New analyst target may drive short‑term buying interest in EWTX.
What to watch
Potential regulatory delays or trial enrollment challenges could temper upside.
Background
Edgewise Therapeutics is advancing its cardiac pipeline after selling its muscular‑dystrophy business.
Ticker impact
Raymond James raised its price target for Edgewise Therapeutics to $85 from $66 after FDA phase‑2 feedback on EDG‑7500.
likely upward pressure as investors price in the higher target.
The new target reflects confidence in the upcoming phase‑3 trial and potential market advantage.
Market effects
Positive outlook may lift other small‑cap biotech stocks focused on cardiac therapies.
U.S. biotech sector could see modest gains.
Limited to investors tracking FDA‑related biotech developments.
Counterpoint
The price target increase may be premature without phase‑3 data; risk of overvaluation.
Key entities
- AnalystRaymond James
Raised price target and maintained Strong Buy rating.
- CompanyEdgewise Therapeutics
Biotech firm developing EDG‑7500 for hypertrophic cardiomyopathy.


